JP2019521990A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521990A5
JP2019521990A5 JP2018565845A JP2018565845A JP2019521990A5 JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5 JP 2018565845 A JP2018565845 A JP 2018565845A JP 2018565845 A JP2018565845 A JP 2018565845A JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5
Authority
JP
Japan
Prior art keywords
composition
use according
item
subject
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565845A
Other languages
English (en)
Japanese (ja)
Other versions
JP6814822B2 (ja
JP2019521990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038003 external-priority patent/WO2017218974A2/en
Publication of JP2019521990A publication Critical patent/JP2019521990A/ja
Publication of JP2019521990A5 publication Critical patent/JP2019521990A5/ja
Application granted granted Critical
Publication of JP6814822B2 publication Critical patent/JP6814822B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565845A 2016-06-16 2017-06-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 Active JP6814822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
US62/351,234 2016-06-16
PCT/US2017/038003 WO2017218974A2 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020155475A Division JP2020203941A (ja) 2016-06-16 2020-09-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置

Publications (3)

Publication Number Publication Date
JP2019521990A JP2019521990A (ja) 2019-08-08
JP2019521990A5 true JP2019521990A5 (https=) 2020-07-02
JP6814822B2 JP6814822B2 (ja) 2021-01-20

Family

ID=60663653

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018565845A Active JP6814822B2 (ja) 2016-06-16 2017-06-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2020155475A Withdrawn JP2020203941A (ja) 2016-06-16 2020-09-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2022113865A Pending JP2022137244A (ja) 2016-06-16 2022-07-15 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2024095160A Pending JP2024113193A (ja) 2016-06-16 2024-06-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2025152535A Pending JP2025186377A (ja) 2016-06-16 2025-09-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020155475A Withdrawn JP2020203941A (ja) 2016-06-16 2020-09-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2022113865A Pending JP2022137244A (ja) 2016-06-16 2022-07-15 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2024095160A Pending JP2024113193A (ja) 2016-06-16 2024-06-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2025152535A Pending JP2025186377A (ja) 2016-06-16 2025-09-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置

Country Status (25)

Country Link
US (2) US20190151409A1 (https=)
EP (3) EP3471780B1 (https=)
JP (5) JP6814822B2 (https=)
KR (2) KR102218265B1 (https=)
CN (2) CN109641065A (https=)
AU (3) AU2017286673B2 (https=)
BR (1) BR112018076124A2 (https=)
CA (1) CA3027737A1 (https=)
CY (1) CY1123697T1 (https=)
DK (2) DK3471780T3 (https=)
ES (2) ES2840059T3 (https=)
FI (1) FI3795181T3 (https=)
HR (2) HRP20251248T1 (https=)
HU (1) HUE051953T2 (https=)
IL (3) IL279919B2 (https=)
LT (2) LT3471780T (https=)
MX (2) MX391779B (https=)
PL (1) PL3795181T3 (https=)
PT (2) PT3471780T (https=)
RS (2) RS67328B1 (https=)
SG (1) SG11201811232XA (https=)
SI (2) SI3471780T1 (https=)
SM (2) SMT202500400T1 (https=)
WO (1) WO2017218974A2 (https=)
ZA (1) ZA201808538B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2840059T3 (es) * 2016-06-16 2021-07-06 Adverum Biotechnologies Inc Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EP4653536A3 (en) 2017-03-17 2026-02-25 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
CN111770999A (zh) * 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
US20210154270A1 (en) * 2018-04-12 2021-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
JP7597380B2 (ja) * 2019-03-04 2024-12-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
WO2020219868A1 (en) * 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
HRP20260137T1 (hr) * 2019-09-11 2026-03-13 Adverum Biotechnologies, Inc. Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept
CA3147843A1 (en) * 2019-09-11 2021-03-18 Mehdi Gasmi Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
TWI819268B (zh) 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
CA3192736A1 (en) * 2020-09-03 2022-03-10 University Of Massachusetts Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
BR112023019056A2 (pt) * 2021-04-27 2024-01-16 Adverum Biotechnologies Inc Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte
AU2023220237A1 (en) 2022-02-21 2024-08-15 Shanghai Regenelead Therapies Co., Ltd Vegf-binding molecule and pharmaceutical use thereof
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
TW202508610A (zh) 2023-08-23 2025-03-01 大陸商上海瑞宏迪醫藥有限公司 醫藥組成物及其用途
WO2025072688A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105755044A (zh) * 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
ES2753135T3 (es) * 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013188316A1 (en) * 2012-06-11 2013-12-19 Avalanche Biotechnologies, Inc. Optical regulation of gene expression in the retina
DK4374873T3 (da) * 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
US11021519B2 (en) * 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2840059T3 (es) * 2016-06-16 2021-07-06 Adverum Biotechnologies Inc Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept

Similar Documents

Publication Publication Date Title
JP2019521990A5 (https=)
JP2019521989A5 (https=)
HRP20201842T1 (hr) Liječenje amd korištenjem aav2 varijante s afliberceptom
HRP20220612T1 (hr) Sastavi i metode za smanjenje očne neovaskularizacije
JP2021503914A5 (https=)
JP2018520646A5 (https=)
Barnett et al. Complications of retinopathy of prematurity treatment
CN115554418B (zh) 一种重组腺相关病毒载体的药物组合物及其用途
CN108368165A (zh) 用于治疗颅内出血相关症状的方法和组合物
JP2018517773A (ja) ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤
JP2018527941A5 (https=)
JP2019509750A (ja) 生弱毒化アルファウイルス構築物及び方法、ならびにそれらの使用
US11000577B2 (en) Compositions and methods for treating neonatal biliary atresia
JP2020510648A5 (https=)
JP2018509154A5 (https=)
JP2023515916A (ja) 神経損傷及び関連障害を治療するための方法
CN117180455A (zh) 腺相关病毒药物组合物及其用途
Aziz et al. Review of gene therapy clinical trials for retinal diseases
JP7616697B2 (ja) ウイルス性肺炎を治療する方法及び薬剤
US20180000892A1 (en) Methods and pharmaceutical compositions for the treatment of ischemic conditions
JP2023525257A (ja) 脊髄性筋萎縮症を治療する方法及び薬剤
JP7850132B2 (ja) ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ
CN118831152A (zh) 导管素抗菌肽在缺血性脑卒中药物中的应用
Ratra Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema
NZ749897B2 (en) Treatment of amd using aav2 variant with aflibercept